Effects of methotrexate and combination of methotrexate-mifepristone in treatment of ectopic pregnancy
Not Applicable
- Conditions
- Pregnancy with abortive outcome.Pregnancy with abortive outcome
- Registration Number
- IRCT201010033461N3
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 66
Inclusion Criteria
stable Hemodynamic state, Without Bleeding or hemo-peritoneum, un ruptured ectopic pregnancy, ectopic pregnancy mass without FHR, ectopic pregnancy mass smaller than 4cm, BHCG less than 1500 mlu/ml, no contradiction of use of methotrexate or mifepristone
Exclusion criteria: decrease in serum BHCG, BHCG less than1500 mlu/ml and depletion after 48 h, history of liver and renal diseases, hematologic or others disorders such as: glaucoma, porphyria, thalassemia, ulcerative colitis, heart diseases, psychological diseases, corticosteroid use more than 6 months, prior sensitivity to methotrexate or mifepristone
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ectopic Pregnancy treatment. Timepoint: Days 4, 7, 11, and 14. Method of measurement: Beta hCG level.
- Secondary Outcome Measures
Name Time Method eed to second methotrexate injection. Timepoint: from 4th to 7th day. Method of measurement: BhcG level.;Rate of infection. Timepoint: 4th, 7th and 11th day after intervention. Method of measurement: temperature more than 38 degree centigrade.;Surgical intervention. Timepoint: 4th day after intervention. Method of measurement: laparatomy.;Number of days required to reduce BhcG level. Timepoint: after 4th day. Method of measurement: Beta hcG level.;Hospital stay. Timepoint: from admission to discharge. Method of measurement: Number of hospitalization dayshospitalization.